Jean-Claude Tardif

Jean-Claude Tardif was born in Laval, Quebec, Canada in 1964. He attended the University of Montreal where he received his MD degree in 1987. Tardif completed his residency at Maisonneuve-Rosemont and Notre-Dame hospitals in Montreal, Canada in 1990. Subsequently, he completed his cardiology fellowship at Sacré-Coeur Hospital and at the Montreal Heart Institute and then his research fellowship at the New England Medical Center of Tufts University School of Medicine in Boston, Massachusetts.

In his work as a clinical trialist, Tardif has designed, conducted, and served as Principal Investigator for trials like COLCOT,[4] Dal-Gene,[5] INITIATIVE and SPIRE.[6] His work contributed to the approval of low-dose colchicine by Health Canada for the prevention of atherothrombotic events in patients with coronary artery disease and its entry into the European guidelines and South American guidelines for cardiovascular prevention.

• 1987-1988, Assistant chief resident, Hôpital Maisonneuve-Rosemont, Montreal, Canada
• 1991, Chief resident, Montreal Heart Institute, Montreal, Canada
• 1991-1992, Resident representative, Cardiology University Department, Université de Montréal
• 1992-1924, Instructor of Medicine, Tufts University School of Medicine, New England Medical Center, Boston, Massachusetts
• 1994-present, Cardiologist, Montreal Heart Institute, Montreal, Canada
• 1994-present, Director, Intravascular Ultrasound Core Laboratory, Montreal Heart Institute, Montreal, Canada
• 1994-1999, Assistant Professor of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, Canada
• 1999-2006, Associate Professor of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, Canada
• 1999-2004, Director of Clinical Research, Research Center, Montreal Heart Institute, Montreal, Canada
• 2003-present, Director, Research Chair, Pfizer Endowed Research Chair in Atherosclerosis, Université de Montréal, Montreal, Canada
• 2004-present, Director, Research Center, Montreal Heart Institute, Montreal, Canada
• 2005-2009, Director, Quebec Cardiovascular Health Network (RSCV), Quebec Health Research Fund (FRSQ)
• 2006-present, Professor of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, Canada
• 2012-2025, Director, Research Chair, Canada Research Chair in Translational and Personalized Medicine

• 1980, Best High School graduate award, College Laval
• 1982-1983, University scholarship, Université de Montréal
• 1987, Rodolphe Boulet-Sandoz award of excellence in medicine at graduation
• 1987, Ciba-Geigy award of excellence in clinical medicine at medical graduation
• 1989, Merck award of excellence in clinical research, Quebec internist meeting
• 1991, Wyeth award of excellence in cardiology, Université de Montreal
• 1992-1924, McLaughlin Foundation of Canada, Grant for research fellowship
• 1998, First Martial Bourassa Award for excellence in research, Montreal Heart Institute
• 1999, Carsley Foundation Award for excellence in research, Montreal Heart Inst.
• 2003-2007,Canadian Institutes of Health Research and Pfizer Research chair in atherosclerosis
• 2004, Quebec Society of Lipidology, Nutrition and Metabolism, Founders' Award
• 2004, Montreal La Presse, Personality of the week
• 2007, Fellow, Canadian Academy of Health Sciences
• 2008, Canadian Cardiovascular Society, Research Achievement Award
• 2008, Montreal La Presse, Personality of the week
• 2008, Montreal La Presse, Personality of the year
• 2011, Bio-Quebec Genesis Brio Award
• 2011, Armand-Frappier Award, Government of Québec
• 2013, Quebec Heart and Stroke Foundation, Cœur Québec Argent Award
• 2014-2015, Professor of the year, Department of Medicine, Université de Montréal
• 2014, Member of the Order of Canada, Government of Canada
• 2015, Distinguished Lecturer in Cardiovascular Sciences, Canadian Institutes of Health Research's Institute of Circulatory Health Award
• 2015, Fellow, European Society of Cardiology
• 2016, Fellow, Canadian Cardiovascular Society
• 2021, Margolese National Heart Disorders Prize
• 2021, Recognition Award, Department of Medicine, Université de Montréal
• 2022, Member, Royal Society of Canada

1- Tardif JC, Rhéaume E, Lemieux-Perreault LP, Grégoire JC, Feroz Zada Y, Asselin G, Provost S, Barhdadi A, Rhainds D, L’Allier PL, Ibrahim R, Upmanyu R, Niesor EJ, Benghozi R, Suchankova G, Laghrissi-Thode F, Guertin MC, Olsson AG, Mongrain I, Schwartz GG, Dubé MP. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet 2015;8:372-382.

This pharmacogenomic study of approximately 6000 patients with coronary artery disease suggested that the effects of the CETP inhibitor dalcetrapib on both cardiovascular outcomes and atherosclerosis imaging are determined by polymorphisms in the ADCY9 gene. Patients with the AA genotype at polymorphism rs1967309 had a 39% reduction in cardiovascular outcomes when treated with dalcetrapib versus placebo.

2- Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PM, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear Cl, Tardif JC. Cardiovascular efficacy and safety of bococizumab in high risk patients. N Engl J Med 2017;376:1527-1539.

In these large phase 3 randomized clinical trials of 27,438 patients, the PCSK9 inhibitor bococizumab was shown to reduce the rate of cardiovascular events in higher-risk patients but not in those at lower risk.

3- Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE; AleCardio Investigators. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the alecardio randomized clinical trial. JAMA 2014; 311:1515-1525.

In this large phase 3 randomized clinical trial, the dual PPAR agonist aleglitazar did not provide cardiovascular benefits in 7226 patients with diabetes and a recent acute coronary syndrome.

4- Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-2257.

In this large-scale randomized clinical trial, the effects of the GLP-1 receptor agonist lixisenatide on cardiovascular outcomes were evaluated in 7000 patients with diabetes and a recent acute coronary syndrome.

5- Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019;38:2497-2505. This international randomized trial of 4745 patients showed that the anti-inflammatory medication colchicine reduces the risk of ischemic cardiovascular events (including strokes) after a myocardial infarction. These results contributed to the approval of colchicine by Health Canada for the prevention of atherothrombotic events in patients with coronary artery disease and its entry in the European guidelines and South American guidelines for cardiovascular prevention.